Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents

References

• Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–499.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212.
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty CR, Evans M, et al. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524–540.
   PubMed Web of Science ®Google Scholar
• Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36(2):167–179.
   PubMed Web of Science ®Google Scholar
• Biederman J, Petty CR, Hammerness P, et al. Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. Br J Psychiatry. 2012;201(3):207–214.
   PubMed Web of Science ®Google Scholar
• Pliszka S, Issues A. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Hagan JF Jr., Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.
   Web of Science ®Google Scholar
• Ritalin LA. (methylphenidate hydrochloride) extended-release capsules. [ cited 2019 Aug 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021284s016s029lbl.pdf
   Google Scholar
• Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577–585.
   Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–364.
   PubMed Web of Science ®Google Scholar
• Quillivant XR. (methylphenidate hydrochloride) for extended-release oral suspension. Highlights of prescribing information. [ cited 2019 Aug 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s006lbl.pdf
   Google Scholar
• Dyanavel XR. (amphetamine) extended-release oral suspension, CII. Highlights of prescribing information. [ cited 2019 Aug 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208147s005lbl.pdf
   Google Scholar
• Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424–433.
   Google Scholar
• McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44(6):530–538.
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13(7):614–620.
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–165.
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–84.
   PubMed Web of Science ®Google Scholar
• Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–179.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed. 2006;8(4):4.
   PubMedGoogle Scholar
• Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85 e2.
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–13.
   PubMed Web of Science ®Google Scholar
• Ozbaran B, Kose S, Yuzuguldu O, et al. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. World J Biol Psychiatry. 2015;16(8):619–624.
   PubMed Web of Science ®Google Scholar
• Taylor A. Food and drug administration pediatric advisory committee meeting Thursday September 20, 2018. [ cited 2019 Sept 08]. Available from: https://www.fda.gov/media/125627/download
   Google Scholar
• Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and safety of dasotraline in children with ADHD: a laboratory classroom study. J Atten Disord. 2019;1087054719864644.
   Web of Science ®Google Scholar
• Johnson JK, Liranso T, Saylor K, et al. A Phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (Extended-release viloxazine) in children with ADHD. J Atten Disord. 2019;1087054719836159.
   Web of Science ®Google Scholar
• Supernus announces P304 Phase III data confirming positive results from previous three Phase III studies on SPN-812 in ADHD. [ cited 2019 Aug 31]. Available from: http://ir.supernus.com/node/11136/pdf
   Google Scholar
• Nageye F, Cortese S. Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother. 2019;19(7):707–717.
   PubMed Web of Science ®Google Scholar
• Highlights of Prescribing Information. INTUNIV® (guanfacine) extended-release tablets, for oral use. [ cited 2019 Aug 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf
   Google Scholar
• Drugs@FDA: FDA Approved Drug Products. New drug application (NDA): 019032. [ cited 2019 Aug 18]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
   Google Scholar
• Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1996;53(5):448–455.
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci. 1988;8(11):4287–4298.
   PubMed Web of Science ®Google Scholar
• Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(1):50–54.
   PubMed Web of Science ®Google Scholar
• Department of health and human services food and drug administration silver spring MD 20993 NDA 22037 NDA APPROVAL. [ cited 2019 Aug 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022037s000ltr.pdf
   Google Scholar
• Treatment for children and adolescents. [ cited 2019 Aug 19]. Available from: https://www.prnewswire.com/news-releases/shire-receives-european-approval-for-intuniv-guanfacine-hydrochloride-prolonged-release-tablets-as-a-non-stimulant-adhd-treatment-for-children-and-adolescents-528461271.html
   Google Scholar
• PRODUCT MONOGRAPH NTUNIV XR* guanfacine hydrochloride extended-release tablets. [ cited 2019 Aug 19]. Available from: https://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/intuniv-xr-pm-en.pdf
   Google Scholar
• Laughren T. NDA 22037/S-002 SUPPLEMENT APPROVAL; [cited 2019 Dec 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022037s002ltr.pdf
   Google Scholar
• Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2007;27(9):1253–1262.
   PubMed Web of Science ®Google Scholar
• Li A, Yeo K, Welty D, et al. Development of guanfacine extended-release dosing strategies in children and adolescents with ADHD using a physiologically based pharmacokinetic model to predict drug-drug interactions with moderate CYP3A4 inhibitors or inducers. Paediatr Drugs. 2018;20(2):181–194.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Robertson B, Sikirica V, et al. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):916–25 e2.
   PubMed Web of Science ®Google Scholar
• Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24(12):1861–1872.
   PubMed Web of Science ®Google Scholar
• Gajria K, Kosinski M, Sikirica V, et al. Psychometric validation of the Weiss functional impairment rating scale-parent report form in children and adolescents with attention-deficit/hyperactivity disorder. Health Qual Life Outcomes. 2015;13:184.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Kollins SH, Wigal TL. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(3):206–214.
   PubMed Web of Science ®Google Scholar
• Stein MA, Sikirica V, Weiss MD, et al. Does guanfacine extended release impact functional impairment in children with attention-deficit/hyperactivity disorder? Results from a randomized controlled trial. CNS Drugs. 2015;29(11):953–962.
   PubMed Web of Science ®Google Scholar
• Sikirica V, Findling RL, Signorovitch J, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs. 2013;27(11):943–953.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875–897.
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6–17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717–728.
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52(9):921–930.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501–510.
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014;53(10):1092–1101.
   PubMed Web of Science ®Google Scholar
• Wilens TE, McBurnett K, Turnbow J, et al. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD. J Atten Disord. 2017;21(2):110–119.
   PubMed Web of Science ®Google Scholar
• van Stralen JPM. A Controlled Trial of Extended-Release Guanfacine and Psychostimulants on Executive Function and ADHD. J Atten Disord. 2018;1087054717751197.
   Web of Science ®Google Scholar
• Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215–226.
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13(12):1047–1055.
   PubMed Web of Science ®Google Scholar
• Huss M, Dirks B, Gu J, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018;27(10):1283–1294.
   PubMed Web of Science ®Google Scholar
• Huss M, McBurnett K, Cutler AJ, et al. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2019;29(3):432–443.
   PubMed Web of Science ®Google Scholar
• Faraone SV, McBurnett K, Sallee FR, et al. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents. Clin Ther. 2013;35(11):1778–1793.
   PubMed Web of Science ®Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53(2):153–173.
   PubMed Web of Science ®Google Scholar
• Martin P, Satin L, Kahn RS, et al. A thorough QT study of guanfacine. Int J Clin Pharmacol Ther. 2015;53(4):301–316.
   PubMed Web of Science ®Google Scholar
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
   PubMed Web of Science ®Google Scholar
• Attention deficit hyperactivity disorder: diagnosis and management. [ cited 2019 Sept 08]. Available from: https://www.guidelines.co.uk/mental-health/nice-adhd-guideline/454106.article
   Google Scholar
• Coghill DR, Banaschewski T, Nagy P, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: A Phase IV, 2-year, open-label study in Europe. CNS Drugs. 2017;31(7):625–638.
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Faraone SV, Biederman J, et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527–537.
   PubMed Web of Science ®Google Scholar
• Li Y, Gao J, He S, et al. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. Mol Neurobiol. 2017;54(9):6655–6669.
   PubMed Web of Science ®Google Scholar
• Childress AC, Sallee FR. Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121–129.
   PubMed Web of Science ®Google Scholar
• Fiks AG, Mayne SL, Song L, et al. Changing patterns of alpha agonist medication use in children and adolescents 2009–2011. J Child Adolesc Psychopharmacol. 2015;25(4):362–367.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Stewart DG, Chan P, et al. The pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016. J Child Adolesc Psychopharmacol. 2019;29:740–745.
   Web of Science ®Google Scholar
• GoodRx prices and coupons for 30 tablets of guanfacine ER 2mg. [ cited 2019 Sept 08]. Available from: https://www.goodrx.com/guanfacine-er
   Google Scholar
• Goel R, Hong JS, Findling RL, et al. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78–95.
   PubMed Web of Science ®Google Scholar
• Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015;172(12):1197–1206.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Hirsch L, Gardner D, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42–51.
   PubMed Web of Science ®Google Scholar
• Strawn JR, Compton SN, Robertson B, et al. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2017;27(1):29–37.
   PubMed Web of Science ®Google Scholar
• Mineur YS, Bentham MP, Zhou WL, et al. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology (Berl). 2015;232(19):3539–3549.
   PubMed Web of Science ®Google Scholar